The FDA's regulatory authority questioned in abortion pill rulings.

A federal judge in Texas has ruled that the FDA improperly approved the abortion pill mifepristone over 20 years ago, raising questions about the agency's regulatory authority. The ruling has led to uncertainty about the future of mifepristone access, with some states stockpiling doses of the drug and pharmaceutical companies expressing support for the FDA. The decision could also have implications for the drug approval process, as judges weighing in on drug approvals could cause the pharmaceutical industry to avoid controversial drugs. Former FDA Commissioner Jane Henney disputes allegations that mifepristone's approval was improperly fast-tracked and says the Texas ruling could cause chaos for medical providers and patients.